Drug Trial Radar · NCT04375800
Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Feb 3, 2021
Primary completion
Nov 12, 2028
Study completion Apr 11, 2034
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- May 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 weeks, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The primary objectives are: * To evaluate the steady state pharmacokinetics (PK) of doravirine (DOR) \[MK-1439\] when given in combination with 2 nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) or as part of the fixed-dose combination (FDC) of DOR/lamivudine (3TC)/tenofovir disproxil fumarate (TDF) in participants ≥6 to \<12 years and weighing ≥14 to \<45 kg. * To evaluate the safety and tolerability of DOR when given with 2 NRTIs or as part of the FDC of DOR/3TC/TDF, in participants ≥6 to 12 years and weighing ≥14 to \<45 kg, through Week 24.
Conditions
- Human Immunodeficiency Virus (HIV) Infection
Interventions
DoravirineDrug
Administered orally
2 NRTIsDrug
Administered orally
DOR/3TC/TDFDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-Time Curve (AUC) From 0 to 24 Hours Postdose (AUC0-24hr) of Doravirine (DOR) Following Once-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
- Maximum Concentration (Cmax) of DOR Following Once-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
- Concentration at 24 Hours (C24) of DOR Following Once-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
- Time to Maximum Concentration (Tmax) of DOR Following Once-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
- AUC From 0 to 12 Hours Postdose (AUC0-12hr) of DOR Following Twice-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
- Cmax of DOR Following Twice-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
- Concentration at 12 Hours (C12) of DOR Following Twice-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
- Tmax of DOR Following Twice-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
- Percentage of Participants With ≥1 Adverse Event (AE)Time frame: Up to 24 weeks
- Percentage of Participants With a Grade 3 or 4 AETime frame: Up to 24 weeks
- Percentage of Participants With Events of DeathTime frame: Up to 24 weeks
- Percentage of Participants Discontinuing From Study Intervention Due to an AETime frame: Up to 24 weeks
- Percentage of Participants Discontinuing From Study Intervention Due to a Drug-Related AETime frame: Up to 24 weeks
Locations
26 sites in 8 countries. Site status is shown where the registry gives one.
University of Colorado at Denver ( Site 0108)
Aurora, Colorado · Completed
Emory Children's Center ( Site 0103)
Atlanta, Georgia · Recruiting
Clinica Somer ( Site 1003)
Rionegro, Antioquia, Colombia · Recruiting
Ciensalud Ips S A S ( Site 1001)
Barranquilla, Atlántico, Colombia · Recruiting
CEIP - Centro de Estudios en Infectología Pediátrica ( Site 1002)
Cali, Valle del Cauca Department, Colombia · Completed
Instituto Dermatológico y Cirugía de Piel "Dr. Huberto Bogaert Díaz" ( Site 1100)
Santo Domingo, Dominican Republic · Recruiting
Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 1201)
Guatemala City, Guatemala · Recruiting
Instituto Nacional de Pediatria ( Site 0701)
Coyoacán, Mexico City, Mexico · Completed
Hospital Infantil de Mexico Federico Gomez ( Site 0702)
Mexico City, Mexico City, Mexico · Active not recruiting
Unidad de Atencion Medica e Investigacion en Salud S.C. ( Site 0700)
Mérida, Yucatán, Mexico · Completed
Kuzbasskiy Center for the Prevention and Control of AIDS ( Site 0506)
Kemerovo, Kemerovo Oblast, Russia · Active not recruiting
Clinical Centre for Prevention and Control of AIDS ( Site 0504)
Krasnodar, Krasnodarskiy Kray, Russia · Completed
Krasnoyarsk Regional Center for Prevention and Control of AIDS ( Site 0507)
Krasnoyarsk, Krasnoyarsk Krai, Russia · Completed
Infectious Clinical Hospital #2 ( Site 0501)
Moscow, Moscow, Russia · Completed
FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 0500)
Saint Petersburg, Sankt-Peterburg, Russia · Active not recruiting
FARMOVS PTY LTD ( Site 0601)
Bloemfontein, Free State, South Africa · Completed
Perinatal HIV Research Unit ( Site 0602)
Johannesburg, Gauteng, South Africa · Recruiting
Wits Reproductive Health and HIV Institute (WRHI) ( Site 0603)
Johannesburg, Gauteng, South Africa · Recruiting
Empilweni Services and Research Unit ( Site 0604)
Johannesburg, Gauteng, South Africa · Completed
King Edward Hospital ( Site 0600)
Durban, KwaZulu-Natal, South Africa · Recruiting
Family Clinic Research With UBUNTU ( Site 0605)
Cape Town, Western Cape, South Africa · Recruiting
Be Part Yoluntu Centre ( Site 0606)
Paarl, Western Cape, South Africa · Recruiting
Tsitsikamma Clinical Research Initiative (TCRI) ( Site 0607)
Plettenberg Bay, Western Cape, South Africa · Completed
Research Institute for Health Sciences ( Site 0902)
Chiang Mai, Thailand · Recruiting
Faculty of Medicine - Khon Kaen University ( Site 0903)
Khon Kaen, Thailand · Recruiting
Siriraj Hospital ( Site 0901)
Bangkok, Bangkok, Thailand · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.